1 February 2021 in International Journal of Infectious Diseases
The aim of this study was to evaluate the diagnostic utility of a novel test kit that could theoretically detect all serogroups of Legionella pneumophila for diagnosing Legionella pneumonia, in comparison with existing kits. This study was conducted in 16 hospitals in Japan from April 2016 to December 2018. Three urinary antigen test kits were used: the novel kit (LAC-116), BinaxNOW Legionella (Binax), and Q-line Kyokutou Legionella (Q-line). In addition, sputum culture and nucleic acid detection tests and serum antibody tests were performed where possible. The diagnostic accuracy and correlations of the novel kit with the two existing kits were analyzed. In total, 56 patients were diagnosed with Legionella pneumonia. The sensitivities of LAC-116, Binax, and Q-line were 79%, 84%, and 71%, respectively. The overall match rate between LAC-116 and Binax was 96.8% and between LAC-116 and Q-line was 96.4%. One patient had L. pneumophila serogroup 2, and only LAC-116 showed a positive result, whereas Binax and Q-line did not. The novel Legionella urinary antigen test kit was useful for diagnosing Legionella pneumonia. In addition, it could detect Legionella pneumonia caused by non-L. pneumophila serogroup 1.
23 September 2022 in Journal of Infection and Chemotherapy
6 November 2024 in Cureus
We present a case of new-onset Graves' disease in a 40-year-old woman following COVID-19 infection. The patient experienced hand tremors, palpitations, shortness of breath with minimal exertion, and excessive sweating one week after recovering from COVID-19. Thyroid function tests revealed thyrotoxicosis, elevated free thyroxine, free triiodothyronine, and suppressed thyroid-stimulating hormone levels. Positive antithyroid peroxidase and thyroid-stimulating hormone (TSH) receptor antibodies, along with ultrasonography findings of diffuse thyroid enlargement and hypervascularization, confirmed the diagnosis of Graves' disease. Scintigraphy was omitted per the patient's request. This case contributes to the growing evidence suggesting SARS-CoV-2 may trigger autoimmune responses leading to thyroid disorders. We discuss the epidemiology, clinical characteristics, and potential mechanisms of Graves' disease following COVID-19, reviewing 28 similar cases reported from 2020 to early 2024. Our analysis reveals varied onset times and severity of thyroid dysfunction post-COVID-19, with some cases progressing to thyroid storm. Our findings highlight the importance of vigilant post-COVID-19 follow-up and contribute to understanding SARS-CoV-2's long-term consequences. From a cost-benefit perspective, a targeted screening approach might be needed for patients with persistent symptoms suggestive of thyroid dysfunction. This strategy could facilitate early detection and treatment, potentially preventing complications and reducing long-term healthcare costs.
30 March 2025 in Diagnostic Microbiology and Infectious Disease